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ABSTRACT 
The aim of the study was to conduct a cluster analysis of pathogenetic 
relationships between metabolic parameters, endothelial lipase levels, the 
severity of steatosis, and clinical parameters in patients with non-alcoholic 
fatty liver disease with hypertension. To analyze pathogenetic 
relationships, a cluster analysis was performed with the distribution of 
parameters into 4 clusters using the Ward's method. The most dense 
metabolic link by cluster analysis endothelial lipase forms with NAFLD 
liver fat score (2.639 cu), HbA1C (2.084 cu), total cholesterol (2.272 cu), 
and alcohol units (2.797 cu). 
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Non-alcoholic fatty liver disease (NAFLD) is the most common cause of impaired liver function 
in adults and children [1]. NAFLD covers the histological spectrum from simple steatosis to non-
alcoholic steatohepatitis (NASH), progressive fibrosis and cirrhosis [2]. Simple steatosis without fibrosis 
or inflammation in most cases has a benign clinical course, but often leads to an increase in mortality [3]. 
The possible role of NAFLD as a risk factor for the development of cardiovascular diseases has been 
discussed for a long time, and only recent data have demonstrated the existing relationship between these 
conditions [4]. Insulin resistance is often detected in patients with NAFLD, as in patients without obesity 
and diabetes [5]. NAFLD is often associated with components of the metabolic syndrome, such as type 2 
diabetes mellitus (T2DM), obesity, hypertension, and dyslipidemia [7]. However, an increasing number 
of patients with a normal body mass index (BMI) have been described, with central obesity and latent 
insulin resistance. [6] Several studies have shown that adopting a healthy lifestyle, reducing weight, and 
proactively correcting individual components of the metabolic syndrome can help prevent, slow down, 
or reverse liver damage associated with NAFLD [8]. 
Endothelial lipase (EL) is a strong determinant of the structural and functional properties of high 
density lipoproteins (HDL) [9]. EL is a new marker of cardiovascular risk, which is closely associated with 
dyslipidemia and insulin resistance and has hardly been studied in the presence of NAFLD [10]. 
Regardless of this, NAFLD increases the risk of premature cardiovascular disease and related 
mortality, therefore, research and monitoring of the metabolic function of the liver and early detection 
of accumulation of EL, as well as the relationships between them, are of great importance. 
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The purpose of the study was to conduct a cluster analysis of pathogenetic relationships 
between metabolic parameters, EL levels and clinical parameters in patients with liver steatosis on the 
background of hypertension.  
Materials and methods 80 patients have been examined on the basis department of internal 
medicine №1 of Kharkiv National Medical University and National Institute of Therapy named by L.T. 
Malaya of National Academy of Medical Sciences of Ukraine.  The patients have been divided into three 
groups according to the severity of liver steatosis. The first group consisted of 16 patients with hypertension 
without laboratory or instrumental signs of liver steatosis (hypertension group). Patients who, in addition to 
hypertension, had signs of steatosis during ultrasound and normal level of transaminases (ALT, AST), 
formed a group with moderate liver steatosis (MLS, n = 20). Patients with hypertension who, in addition to 
the echoscopic features of hepatic steatosis had increased level of transaminases, were assigned to the 
group with severe liver steatosis (group SLS, n = 24). The control group consisted of 20 practically healthy 
individuals. The patients' ages ranged from 45 to 60 years, with an average age of 52.12 + 5.24 years. 
Among them 28 were female (46.66%) and 32 were male (53.33%). 
for identification of liver steatosis and its severity we have used liver fat index (NAFLD liver 
fat score), which includes such indicators as the presence of metabolic syndrome and T2DM, serum 
insulin level, AST and the ratio AST/ALT and is calculated by the formula [11]: 
NAFLD liver fat score= - 2.89+1.18×metabolic syndrome (yes=1/no=0)+ 0.45×type 2 diabetes 
(yes=2/no=0)+0.15× fasting serum Insulin (mU/L)+ 0.04 × fasting serum АSТ(U/L) – 0.94 × АSТ/АLТ. 
The FIB-4 index has been used to identify liver fibrosis, which includes indicators such as 
AST, ALT, platelet count, and is calculated by the formula [12]: 
FIB4 = Age (years) ×AST (IU/L)/platelet count (×109/L)×√ALT (IU/L) 
Serum endothelial lipase (EL) concentration was determined by enzyme-linked 
immunosorbent assay using Aviscera Bioscience INC reagent kit (USA) using a Labline 90 enzyme 
immunoassay analyser. 
For excluding the alcoholic genesis of NAFLD all patients have been interviewed to determine 
alcohol units. This test has international standardization and allows detecting alcohol abuse by the formula: 
Alcohol units = amount (liters) × alcoholic strength (%) × 0.789  
Alcohol abuse was eliminated by less than 14 units per week regardless of gender [13]. 
In order to monitor the implementation of dietary recommendations, we have used a questionnaire 
designed by the original questionnaire, which asked patients about the consumption of 15 basic foods that 
are not recommended for overweight, carbohydrate metabolism disorders and liver steatosis. 
The statistical processing of the survey data has been performed using Microsoft Exel and 
Statistica 7.0 using standard methods of virion statistics. 
Results and discussion. Results of studies are presented in table 1. 
Table 1. Anthrometric, laboratory and surrogate ratios indicating the severity of liver steatosis 
Parameter 
Control, 
n=20 
Hypertension 
group, 
n=16 
MLS group, 
n=20 
SLS group, 
n=24 Significance of 
difference, P 
0 1 2 3 
Mean SD Mean SD Mean SD Mean SD  
1 2 3 4 5 6 7 8 9 10 
AST/ALT, U 0.73 0.34 0,95 0,26 1,19 0,38 1,75 0,77 12, 23, 13 
ALT, U/L 18,15 7,26 22,44 6,29 24,65 7,19 62,54 40,78 23, 13 
АSТ, U/L 11,45 3,78 24,56 7,84 22,90 10,18 38,71 20,70 23, 13 
AP, mmol/l 1334,90 464,11 1422,50 302,46 1457,13 384,29 1834,06 690,13 13, 23 
NAFLD liver fat 
score 
-1,93 0,65 -0,308 1,14 2,308 2,43 4,48 3,21 For all groups < 0,001 
Fib-4 0,43 0,16 1,07 0,36 1,14 0,72 1,36 0,63 
With control - all groups< 
0.0001 
13, 23 
BMI, kg/m2 21,44 1,57 25,91 3,42 30,00 2,79 29,04 5,44 01, 02, 03, 12 
WC, cm 75,50 6,83 79,31 8,58 98,08 10,53 104,10 8,67 02, 03, 12, 13, 23 
WC/height, U 0,44 0,03 0,47 0,04 0,57 0,05 0,60 0,04 01, 02, 03, 12, 13, 23 
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Continuation of table 1 
1 2 3 4 5 6 7 8 9 10 
SBP, mm Hg 116,00 4,17 161,56 17,77 163,89 17,54 169,17 22,20 01, 02, 03 
DBP, mm Hg 73,50 5,16 101,56 7,47 102,78 8,26 101,46 9,94 01, 02, 03 
Cholesterol, mmol/l 3,85 0,77 5,25 1,47 5,74 0,85 5,80 1,42 01, 02, 03 
Triglycerides, mmol/l 0,92 0,16 1,13 0,38 1,70 
0,83 
0,33 
1,96 
0,67 
0,37 
12, 13, 23 
HDL, mmol/l 1,77 0,28 1,47 0,42 1,42 0,30 1,20 0,27 13, 23 
LDL, mmol/l 2,36 0,46 3,45 1,41 3,34 0,85 3,75 1,25  
VLDL, mmol/l 0,38 0,05 0,56 0,16 0,70 0,40 0,92 0,31  13, 23 
EL, ng / ml 8,23 2,47 10,54 2,69 13,21 3,59 13,71 3,71 01, 02, 03, 12, 13 
Diet 2,36 0,81 2,57 0,53 2,64 1,15 2,08 0,86  
Alcohol units 4,26 2,27 4,29 1,82 6,39 2,99 6,62 2,98 02, 03, 12, 13 
Fasting glucose, 
mmol/l 
4,36 0,72 5,01 0,60 6,32 1,75 5,73 0,91 12, 13 
Fasting insulin, mU/l 7, 91 3,71 17,77 6,86 24,51 9,49 33,28 13,82 12, 13, 23 
HOMA-IR 1,55 0,85 3,61 1,80 7,02 4,76 8,35 5,25 12, 13 
HbA1C, % - - 5,40 0,63 6,64 1,76 5,79 0,49 12, 23, 13 
 
For the analysis of pathogenetic relationships, a cluster analysis was performed. The graph of 
parameter merging using Ward's method showed that it is advisable to distribute data into 3-4 clusters (Fig. 1). 
 
Fig. 1. Cluster aggregation of data parameters 
The first and second cluster illustrates the existence of offline hypertension and the close 
relationship of hyperinsulinism with BMI. 
The third cluster covered liver steatosis associated with alcohol consumption, compensation 
for carbohydrate metabolism (by HbA1C) and the level of total cholesterol and EL. 
The fourth cluster demonstrates the connection of lipid profile parameters with the patient's 
nutritional preferences (Table 2). 
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Table 2. Clustering of model components containing parameters of lipid-carbohydrate 
metabolism with hypertension and liver steatosis 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
Parameter Mean Parameter Mean  Parameter Mean Parameter Mean 
SBP 33,04 
Fasting 
insulin  
8,520 HbA1C 2,084 Triglycerides 0,840 
DBP 33,04 BMI 8,520 EL 5,386 HDL 1,231 
    Cholesterol 2,272 LDL 1,864 
    
Alcohol 
units 
2,797 VLDL 1,470 
    
NAFLD 
liver fat 
score 
2,639 Diet 1,306 
      WC/height 1,472 
 
Grouping the results of the examination of patients allowed us to identify 4 main clusters. 
Cluster 1 - overweight patients with abdominal fat distribution and moderate hypertension, moderate 
hyperinsulinism with prediabetic levels of HbA1C, increased levels of total cholesterol, LDL and 
borderline HDL, moderate steatosis (table 3). 
 
Table 3. Basic statistical analysis of clinical and laboratory parameters Cluster 1 
Parameters Valid N Mean Minimum Maximum Variance Std.Dev. Coef.Var. 
WC/height 13 0,5391 0,3593 0,6221 0,00544 0,073755 13,68212 
Fasting insulin 13 25,0715 15,7000 46,0500 93,55990 9,672637 38,58015 
HbA1C 13 6,1092 4,3300 10,3000 2,36916 1,539207 25,19477 
EL 13 12,0465 7,0665 17,4200 9,18047 3,029928 25,15198 
Cholesterol 13 5,9615 4,0200 7,7900 1,40600 1,185748 19,88996 
Triglycerides 13 1,4846 0,7900 4,1600 0,73911 0,859715 57,90828 
HDL 13 1,4046 0,6900 2,0000 0,13968 0,373734 26,60755 
LDL 13 3,7492 2,2800 5,3500 0,86937 0,932402 24,86917 
VLDL 13 0,6277 0,1900 1,8700 0,16587 0,407270 64,88377 
SBP 13 142,6923 130,0000 150,0000 52,56410 7,250111 5,08094 
DBP 13 94,6154 80,0000 100,0000 56,08974 7,489309 7,91553 
BMI 13 27,5394 16,8525 32,4500 17,56233 4,190744 15,21728 
Alcohol units 13 6,4231 2,0000 9,2000 5,46692 2,338145 36,40226 
Diet 13 2,7692 1,0000 4,0000 0,85897 0,926809 33,46809 
NAFLD liver fat score 13 2,1543 -0,8161 6,1263 3,98455 1,996134 92,65719 
 
Cluster 2 included patients with grade 1 obesity with severe abdominal fat distribution and 
severe hypertension, a pre-diabetic level of HBA1C, an increase in total cholesterol, triglycerides, 
LDL and a distinct decrease in HDL and severe liver steatosis (Table 4). 
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Table 4. Basic statistical analysis of clinical and laboratory indicators of representatives of Cluster 2 
Parameters Valid N Mean Minimum Maximum Variance Std.Dev. Coef.Var. 
WC/height 11 0,5934 0,5058 0,7317 0,0038 0,06164 10,38688 
Fasting insulin 11 53,0082 35,3300 73,3500 172,3410 13,12787 24,76574 
HbA1C 11 6,0109 4,8600 7,4400 0,9214 0,95992 15,96965 
EL 11 13,6655 7,7600 19,7200 21,8332 4,67261 34,19283 
Cholesterol 11 6,4600 4,1500 8,5500 1,4985 1,22414 18,94954 
Triglycerides 11 2,5227 0,9700 5,6900 1,8036 1,34298 53,23534 
HDL 11 1,0718 0,7600 1,5600 0,0545 0,23340 21,77624 
LDL 11 4,2218 1,9400 6,4000 1,8807 1,37138 32,48310 
VLDL 11 1,0982 0,3700 2,5600 0,4095 0,63995 58,27362 
SBP 11 175,9091 160,0000 180,0000 54,0909 7,35465 4,18094 
DBP 11 105,0000 100,0000 120,0000 45,0000 6,70820 6,38877 
BMI 11 30,0625 22,9481 48,3343 51,2784 7,16089 23,82002 
Alcohol units 11 6,1909 1,5000 10,0000 8,6669 2,94396 47,55298 
Diet 11 2,9091 1,0000 4,0000 1,0909 1,04447 35,90352 
NAFLD liver fat score 11 6,8779 0,9228 10,9828 11,5463 3,39799 49,40435 
 
Cluster 3 was composed of overweight patients with abdominal fat distribution, a slight 
increase in insulin at normal HbA1C, a slight increase in total cholesterol and LDL, normal 
triglycerides and marginal HDL (Table 5). 
 
Table 5. Basic statistical analysis of clinical and laboratory indicators of representatives of Cluster 3 
Parameters Valid N Mean Minimum Maximum Variance Std.Dev. Coef.Var. 
WC/height 23 0,5448 0,4606 0,6875 0,00439 0,066239 12,1574 
Fasting insulin 23 18,1643 4,8600 37,1000 85,67632 9,256150 50,9578 
HbA1C 23 5,6678 4,3700 7,2800 0,61653 0,785192 13,8535 
EL 23 11,2209 5,3300 18,9900 10,31109 3,211089 28,6171 
Cholesterol 23 5,3009 2,8400 6,9900 1,65284 1,285627 24,2531 
Triglycerides 23 1,3804 0,7500 2,6900 0,29569 0,543770 39,3912 
HDL 22 1,3318 0,8000 2,3000 0,11832 0,343977 25,8276 
LDL 22 3,2109 1,0000 5,1600 1,38308 1,176042 36,6265 
VLDL 23 0,6991 0,3400 1,5000 0,10728 0,327538 46,8493 
SBP 23 168,2609 150,0000 180,0000 53,65613 7,325034 4,3534 
DBP 23 103,0435 100,0000 120,0000 31,22530 5,587960 5,4229 
BMI 23 28,1174 22,6003 37,1255 13,17259 3,629407 12,9080 
Alcohol units 23 5,3000 1,5000 11,5000 8,36909 2,892938 54,5837 
Diet 23 3,0000 1,0000 4,0000 0,90909 0,953463 31,7821 
NAFLD liver fat score 23 0,8359 -2,7277 4,9742 4,40681 2,099239 251,1388 
 
Cluster 4 is the least numerically representative, but the most unexpected. It included patients 
with severe abdominal obesity, diabetic levels of HbA1C, moderate hyperinsulinism, with an increase 
in total cholesterol, TG, LDL and a decrease in HDL (Table 6). 
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Table 6. Basic statistical analysis of clinical and laboratory indicators of representatives of Cluster 4 
Parameters Valid N Mean Minimum Maximum Variance  Std.Dev. Coef.Var. 
WC/height 5 0,5782 0,4821 0,6180 0,0032  0,05692 9,84298 
Fasting insulin 5 21,9720 16,1700 27,5400 26,5516  5,15283 23,45179 
HbA1C 5 6,6280 5,4200 9,9600 4,8687  2,20652 34,86912 
EL 5 13,9380 9,2300 18,2800 14,5143  3,80977 27,33367 
Cholesterol 5 5,6600 4,6000 6,7600 0,7388  0,85951 15,18561 
Triglycerides 5 2,2500 1,2300 3,2900 0,8322  0,91222 40,54322 
HDL 5 1,1440 0,7800 1,6100 0,1012  0,31817 27,81177 
LDL 5 3,5060 2,4400 4,5000 0,6001  0,77468 22,09585 
VLDL 5 1,0000 0,5000 1,4800 0,1811  0,42562 42,56172 
SBP 5 203,0000 190,0000 240,0000 445,0000  21,09502 10,39164 
DBP 5 114,0000 100,0000 130,0000 130,0000  11,40175 10,00154 
BMI 5 30,1405 24,8016 33,9100 12,8248  3,58118 11,88161 
Alcohol units 5 6,8800 4,5000 11,5000 10,6970  3,27063 47,53818 
Diet 5 2,6000 2,0000 3,0000 0,3000  0,54772 21,06625 
NAFLD liver fat score 5 1,7530 0,2018 2,9370 1,5633  1,25032 71,32395 
 
For better visualization, we have reduced the average values of the parameters for the clusters 
into a common table (Table 7), which allows us to compare trends. 
Table 7. The average values of clinical and laboratory indicators with the distribution of clusters 
Parameters 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
WC/height 0,54 0,59 0,54 0,58 
Fasting insulin 25,07 53,01 18,16 21,97 
HbA1C 6,11 6,01 5,67 6,33 
EL 12,05 13,67 11,22 13,94 
Cholesterol 5,96 6,46 5,30 5,66 
Triglycerides 1,48 2,52 1,38 2,25 
HDL 1,40 1,07 1,33 1,14 
LDL 3,75 4,22 3,21 3,51 
VLDL 0,63 1,10 0,70 1,00 
SBP 142,69 175,91 168,26 203,00 
DBP 94,62 105,00 103,04 114,00 
BMI 27,54 30,06 28,12 30,14 
Alcohol units 6,42 6,19 5,30 6,88 
Diet 2,77 2,91 3,00 2,60 
NAFLD liver fat score 2,15 6,88 0,84 1,75 
 
The lowest variability of characteristics in the first cluster is inherent in indicators of blood 
pressure, BMI and insulin concentration, and the largest - in the severity of liver steatosis. 
The lowest variability in the second cluster is inherent in blood pressure and anthropometric 
parameters, as well as indicators of carbohydrate metabolism. The variability of the severity of 
steatosis is half that of the previous group. 
Cluster 3 from cluster 1 is distinguished by lower numbers of blood pressure, less severe liver 
steatosis and less alcohol abuse. The indicated group is determined by the relative stability of lipid 
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profile parameters, the stability of carbohydrate metabolism compensation, but the high variability of 
NAFLD. Thus, it is understood that the formation of steatosis is not latent even under conditions of a 
moderate shift in metabolic parameters. 
Cluster 4 from cluster 2 is distinguished by pronounced hypertension, low insulin values, less 
compensation for carbohydrate metabolism, but also less severity of liver steatosis. In addition, 
alcohol abuse is the highest in this group, and the lowest adherence to dietary recommendations. The 
fact that dyslipidemia is isolated is also obvious, which is confirmed by the data of a large population 
study under the auspices of NHANES, which included more than 23 thousand Americans, in patients 
with hepatic pathology with high levels of transaminases lipid profiles with low LDL and high HDL 
can be recorded, which may be caused by a defect in the synthesis of lipoproteins or a violation of the 
synthetic function of the liver and a marker of latent hepatopathies [14]. 
Conclusions. 1. Clustering of patient examination results demonstrates a reliable distribution 
of groups according to the severity of liver steatosis. 
2. In case of non-compliance with dietary recommendations and the use of alcohol even within 
acceptable limits, the progression of liver steatosis occurs even against the background of minimal 
metabolic disturbances 
3. The presence of genetically determined hyperlipidemia in combination with insulin 
resistance is an unfavorable background in the implementation of the clinical manifestations of 
metabolic disorders.  
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